Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

SCHLIEREN (Zurich), Switzerland, March 13, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a phase IIa study with CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderate allergic rhinitis due to grass pollen allergy (hay fever). The trial investigated in a doubleblind setting the safety, tolerability and exploratory efficacy of two different formulations of CYT003-QbG10 monotherapy to placebo, and in an open-label setting a CYT003-QbG10 formulation comprising a low dose of grass pollen extract. Exploratory efficacy of CYT003-QbG10 was determined by assessing the allergic disease status of the patients before and after treatment by the conjunctival provocation test, yielding a symptom score ranging from 0 to 15 points.

All formulations of CYT003-QbG10 tested were safe and well tolerated. Treatment with CYT003-QbG10 monotherapy led to a significant (p<0.05) improvement of allergy symptoms in the conjunctival provocation test when compared to placebo. A reduction of the median symptom score from 9 points pre-treatment to 5 points post-treatment was achieved (for placebo: 9 points pre-treatment to 8 points post-treatment). For the formulation of CYT003-QbG10 plus grass pollen extract, the median symptom score was reduced from 9 points pre-treatment to 4 points post-treatment, whereas for the formulation of CYT003-QbG10 plus alum, no significant reduction was observed when compared to placebo.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented: "These results mark a further important milestone in the development of CYT003-QbG10 monotherapy and confirm prior open-label observations of efficacy of this product in a double-blind, placebo-controlled setting. At this stage, we are assessing various parameters of this promising Immunodrug™ candidate such as different formulations,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/3/2015)... Israel , August 3, 2015 ... received the statistical analysis of results from a study which ... BVX-005 phase II trial which took place in 2012, provided ... exist at the time of the study- in particular the ... epidemic in the United States in ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
(Date:8/3/2015)... -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) announced ... agreement to develop and commercialize multiple prespecified and undisclosed ... company for premier antibody development and manufacturing companies in ... the terms of the agreement, Sorrento will develop and ... American, European and Japanese market. Each of the mAbs ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4
(Date:8/3/2015)... California (PRWEB) , ... August 03, 2015 , ... Did ... or Orange County looking for exceptional and affordable home care options which A-1 ... services are just a few of the credentials A-1 Home Care Agency ...
(Date:8/2/2015)... ... August 03, 2015 , ... ... attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) conference being ... are pleased for the opportunity the AHDI conference provides us to interact with ...
(Date:8/2/2015)... ... 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can prove ... afford to start a business.” Neither needs be a major obstacle. , The U.S. ... start a business and be successful. The risks of starting a business can be high ...
(Date:8/2/2015)... ... August 02, 2015 , ... Molecular biologists in New ... indicator for mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... New South Wales tested for Ki67 expression in tissue samples from 42 patients with ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
Breaking Medicine News(10 mins):Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2
... HealthDay Reporter , TUESDAY, Sept. 20 (HealthDay News) -- ... children and teens with obsessive-compulsive disorder, new research shows. ... of the Journal of the American Medical Association ... and obsessive-compulsive disorder (OCD). "[If] a child ...
... against methamphetamine and nicotine have been selected to receive ... The two scientists, Dr. Thomas Kosten, of Baylor ... the University of Connecticut, Storrs, will each receive $500,000 ... according to the National Institute on Drug Abuse (NIDA), ...
... , TUESDAY, Sept. 20 (HealthDay News) -- New research ... saved money used for diagnosis and boosted the likelihood that ... follow-up appointments. But there,s a big catch. Researchers ... to $649 on average -- compared to the usual $3,500 ...
... Health (NIH) has awarded nearly $2 million to researchers ... to develop a new class of therapeutics for treating ... project focuses on developing biomaterials capable of capturing certain ... wound sites to enhance tissue regeneration in adults. By ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, Sept. ... breast, babies seem to turn out smarter when nourished with ... two new studies indicate. The studies, done in the ... the journal Pediatrics , found that higher levels of ...
... Foundation,s Discovery Campaign, which seeks to further the growth ... announced a major corporate pledge to that initiative. St. ... Medical, has pledged $100,000 and is a "Pioneer" level ... strengthens SIR Foundation,s Discovery Campaign as it paves the ...
Cached Medicine News:Health News:Adding Psychotherapy to Meds Helps Kids With OCD 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 3Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 2Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2
... After inserting a finger into comfortable ... on, and continuous measurement is performed., ... character height. In darker surroundings, back ... reading., ,Light weight, compact contour ...
... The Autocorr Pulse Oximeter with SAC (Serial ... patented software to extract SpO 2 , ... a new way. This cost-effective compact ... functions as standard features, and a data ...
... fourth in the Clarity Series is ... with 3 or 5 lead ECG, ... (Serial Autocorrelation) technology, and respiration. ... two user configurable traces. An ...
... BCI 3180 Pulse Oximeter is a cost-effective, ... 2 pulse rate and pulse strength ... This AC or battery powered unit ... alarm limits and up to 30 hours ...
Medicine Products: